The 17-gene signature developed in this study differs fundamentally in purpose and clinical context from established multigene assays, such as Oncotype DX and MammaPrint, which were designed and validated to predict recurrence risk and guide adjuvant treatment decisions in hormone receptor-positive, HER2-negative breast cancer [37,42]. This evidence concerns the gene NR4A1 and breast carcinoma.